Caregiving in a time of Coronavirus
A message from your Alzheimer’s Disease Research Center
University of Pittsburgh
Alzheimer’s Disease Research Center
The University of Pittsburgh Alzheimer’s Disease Research Center (ADRC) is one of the nation’s leading research centers specializing in the diagnosis of Alzheimer’s disease and related disorders.
Memory Evaluation
Donate Now
Upcoming Events
The University of Pittsburgh Alzheimer’s Disease Research Center (ADRC) is one of the nation’s leading research centers specializing in the diagnosis of Alzheimer’s disease and related disorders. Through outpatient evaluations, participants and their families receive state-of-the-art diagnostic assessments and contribute to the scientific study of Alzheimer’s disease.
ADRC Memory Evaluation and Participation in the Research Center
Zinna has been participating since 2014
read more from Zinna and other ADRC volunteers…
Our memory evaluation is an extensive diagnostic evaluation of individuals with suspected Alzheimer’s disease and other types of memory loss and/or cognitive impairment. The professionals at the ADRC understand that this is a stressful process for all and assure that individuals will be treated with sensitivity and respect.
Dementia with Lewy Bodies Consortium
Description: The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers improve the diagnosis, care, and treatment of patients with this disease.
Study Length: 5 years
Study Requirements:
Age 40-90
Diagnosis of Lewy Body Dementia (DLB) or high likelihood
A study partner who will accompany you to all study visits
Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
Alzheimer’s Disease Neuroimaging Initiative – 3 (ADNI3)
Description: The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection. For more information about the ADNI3 study visit http://www.adni-info.org
Study Length: up to 5 years
Study Requirements:
55-90 years of age
Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
A study partner who will accompany you to all study visits
Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)
Description: The study is designed to examine the efficacy and safety of escitalopram in combination with a psychosocial intervention (PSI) as treatment for agitation in AD patients.
Study Length: 6 months
Study Requirements:
Diagnosis of Alzheimer’s disease with significant agitation/aggression
A study partner who will accompany you to all study visits
Contact:
Patricia Henderson 412-692-2703 or hendersonpl@upmc.edu
FORAging – Facilitating Optimal Routines in Aging
Description: This study is looking at ways to minimize problems with everyday tasks by using a new strategy.
Study Length: 12 months
Study Requirements:
60 years of age AND
Having difficulty managing daily tasks
Contact:
MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
PROTECT Depression Research Study
Description: The aim of this study is to understand why some people become depressed and have thoughts of hurting themselves while others do not.
Study Length: 2-3 sessions lasting 2-4 hours each
Study Requirements:
- 50 years old or older
- Recently been feeling depressed
- Never been diagnosed with bipolar depression, a psychotic or neurological disorder
- Never had a stroke
Contact: 412-246-6014 or PROTECT.study@upmc.edu
ADRC Video Spotlight
ADRC participant, Jean, shares her experience at Pitt’s Alzheimer’s Disease Research Center.
Pathways Newsletter
The Spring/Summer 2022 edition of the Pathways Newsletter is now available.